EUVIMEDEUVIMED entdecken
Open Access

The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure

Raymond Kwan, Lu Chen, Min-Jung Park, Zemin Su, Sujith V W Weerasinghe, William M Lee, Valerie L Durkalski-Mauldin, Robert J Fontana, M Bishr Omary

Clinical Gastroenterology and Hepatology · 2023

DOI: 10.1016/j.cgh.2023.03.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Raymond Kwan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscat…. Hauptthemen laut MEDLINE: End Stage Liver Disease, Liver Failure, Acute. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Carbamoyl phosphate synthetase 1 (CPS1) is a highly abundant mitochondrial urea cycle enzyme that is expressed primarily in hepatocytes. CPS1 is constitutively and physiologically secreted into bile but is released into the bloodstream upon acute liver injury (ALI). Given its abundance and known short half-life, we tested the hypothesis that it may serve as a prognostic serum biomarker in the setting of acute liver failure (ALF). METHODS: CPS1 levels were determined using enzyme-linked immunosorbent assay and immunoblotting of sera collected by the ALF Study Group (ALFSG) from patients with ALI and ALF (103 patients with acetaminophen and 167 non-acetaminophen ALF etiologies). A total of 764 serum samples were examined. The inclusion of CPS1 was compared with the original ALFSG Prognostic Index by area under the receiver operating characteristic curve analysis. RESULTS: CPS1 values for acetaminophen-related patients were significantly higher than for non-acetaminophen patients (P < .0001). Acetaminophen-related patients who received a liver transplant or died within 21 days of hospitalization exhibited higher CPS1 levels than patients who spontaneously survived (P = .01). Logistic regression and area under the receiver operating characteristic analysis of CPS1 enzyme-linked immunosorbent assay values improved the accuracy of the ALFSG Prognostic Index, which performed better than the Model for End-Stage Liver Disease, in predicting 21-day transplant-free survival for acetaminophen- but not non-acetaminophen-related ALF. An increase of CPS1 but not alanine transaminase or aspartate transaminase, when comparing day 3 with day 1 levels was found in a higher percentage of acetaminophen transplanted/dead patients (P < .05). CONCLUSION: Serum CPS1 determination provides a new potential prognostic biomarker to assess patients with acetaminophen-induced ALF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

End Stage Liver DiseaseLiver Failure, AcuteHumansAcetaminophenBiomarkersCarbamyl PhosphateLigasesPrognosisSeverity of Illness IndexCarbamoyl-Phosphate Synthase (Ammonia)

Stichwörter der Autor:innen

BiomarkerLiver InjuryMitochondria

Substanzen

AcetaminophenBiomarkersCarbamyl PhosphateLigasesCPS1 protein, humanCarbamoyl-Phosphate Synthase (Ammonia)

Autor:innen und Institutionen

  • Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ; Switch Therapeutics, Inc, San Francisco, CA.
  • Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ; Department of Infectious Disease, Ruijin Hospital, Shanghai…
  • Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.
  • Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.
  • Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ.
  • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX.

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • University of Michigan

Zitieren

APA

Kwan, R., Chen, L., Park, M. J., Su, Z., Weerasinghe, S. V. W., Lee, W. M., Durkalski-Mauldin, V. L., Fontana, R. J., & Omary, M. B. (2023). The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.03.002

Vancouver

Kwan R, Chen L, Park MJ, Su Z, Weerasinghe SVW, Lee WM, et al. The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.03.002

BibTeX
@article{Kwan2023,
  author = {Kwan, Raymond and Chen, Lu and Park, Min-Jung and Su, Zemin and Weerasinghe, Sujith V W and Lee, William M and Durkalski-Mauldin, Valerie L and Fontana, Robert J and Omary, M Bishr},
  title = {The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1016/j.cgh.2023.03.002}
}
Kostenlos starten →